Research ArticleOriginal Research

“Finding the Right FIT”: Rural Patient Preferences for Fecal Immunochemical Test (FIT) Characteristics

Robyn Pham, Suzanne Cross, Bianca Fernandez, Kathryn Corson, Kristen Dillon, Coco Yackley and Melinda M. Davis
The Journal of the American Board of Family Medicine September 2017, 30 (5) 632-644; DOI: https://doi.org/10.3122/jabfm.2017.05.170151

References

  1. 1.↵
    Colorectal Cancer Facts & Figures 2014–2016. Atlanta, GA: American Cancer Society; 2014.
  2. 2.↵
    1. Zauber AG,
    2. Lansdorp-Vogelaar I,
    3. Knudsen AB,
    4. et al
    . Evaluating test strategies for colorectal cancer screening: A decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:659–69.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Whitlock EP,
    2. Lin JS,
    3. Liles E,
    4. et al
    . Screening for colorectal cancer: A targeted, updated systematic review for the U.S. preventive services task force. Ann Intern Med 2008;149:638–58.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Morbidity, and Mortality Weekly Report (MMWR). Vital signs: Colorectal cancer screening test use—United States, 2012. MMWR Morb Mortal Wkly Rep 2013;62:881–8.
    OpenUrlPubMed
  5. 5.↵
    1. Society AC
    . Colorectal Cancer Facts & Figures 2017–2019. Atlanta, GA: American Cancer Society; 2017.
  6. 6.↵
    80% by 2018. 2016. Available from: http://nccrt.org/tools/80-percent-by-2018. Accessed on January 23, 2017.
  7. 7.↵
    1. Sabatino SA,
    2. White MC,
    3. Thompson TD,
    4. et al
    . Cancer screening test use—United States, 2013. MMWR Morb Mortal Wkly Rep 2015;64:464–8.
    OpenUrlPubMed
  8. 8.↵
    1. Cole AM,
    2. Jackson JE,
    3. Doescher M
    . Urban-rural disparities in colorectal cancer screening: Cross-sectional analysis of 1998–2005 data from the Centers for Disease Control's Behavioral Risk Factor Surveillance Study. Cancer Med 2012;1:350–6.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Davis MM,
    2. Pham R,
    3. et al
    . Geographic and popluation-level disparities in colorectal cancer screening: A multilevel analysis if medicaid and commercial claims data. Prev Med 2017;101:44–52.
    OpenUrl
  10. 10.↵
    1. Gupta S,
    2. Sussman DA,
    3. Doubeni CA,
    4. et al
    . Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst 2014;106(4):dju032.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Lieberman D,
    2. Ladabaum U,
    3. Cruz-Correa M,
    4. et al
    . Screening for colorectal cancer and evolving issues for physicians and patients: A review. JAMA 2016;316:2135–45.
    OpenUrl
  12. 12.↵
    United States Preventive Services Task Force (USPSTF). Final Update Summary: Colorectal Cancer: Screening. 2016.
  13. 13.↵
    1. Honein-AbouHaidar GN,
    2. Kastner M,
    3. Vuong V,
    4. et al
    . Benefits and barriers to participation in colorectal cancer screening: a protocol for a systematic review and synthesis of qualitative studies. BMJ Open 2014;4(2):e004508.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Mackie A
    . Moving from guaiac faecal occult blood test (gFOBT) to a faecal immunochemical test for haemoglobin (FIT) in the bowel screening programme: A consultation. 2015.
  15. 15.↵
    1. Levin B,
    2. Lieberman DA,
    3. McFarland B,
    4. et al
    . Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58(3):130–60.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Levin TR,
    2. Zhao W,
    3. Conell C,
    4. et al
    . Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med 2006;145:880–6.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Hoffman RM,
    2. Espey D,
    3. Rhyne RL
    . A public-health perspective on screening colonoscopy. Expert Rev Anticancer Ther 2011;11:561–9.
    OpenUrlPubMed
  18. 18.↵
    1. Panteris V,
    2. Haringsma J,
    3. Kuipers EJ
    . Colonoscopy perforation rate, mechanisms and outcome: From diagnostic to therapeutic colonoscopy. Endoscopy 2009;41:941–51.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Schoenberg NE,
    2. Eddens K,
    3. Jonas A,
    4. et al
    . Colorectal cancer prevention: Perspectives of key players from social networks in a low-income rural US region. Int J Qual Stud Health Well-being 2016;11(1):30396.
    OpenUrl
  20. 20.↵
    1. Bowyer HL,
    2. Vart G,
    3. Kralj-Hans I,
    4. et al
    . Patient attitudes towards faecal immunochemical testing for haemoglobin as an alternative to colonoscopic surveillance of groups at increased risk of colorectal cancer. J Med Screen 2013;20(3):149–56.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Ruffin MT 4th.,
    2. Creswell JW,
    3. Jimbo M,
    4. Fetters MD
    . Factors influencing choices for colorectal cancer screening among previously unscreened African and Caucasian Americans: Findings from a triangulation mixed methods investigation. J Community Health 2009;34(2):79–89.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Green BB,
    2. Coronado GD,
    3. Devoe JE,
    4. et al
    . Navigating the murky waters of colorectal cancer screening and health reform. Am J Public Health 2014;104:982–6.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Inadomi JM,
    2. Vijan S,
    3. et al
    . Adherence to colorectal cancer screening: A randomized clinical trial of competing strategies. Arch Intern Med 2012;172:575–82.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Shokar NK,
    2. Carlson CA,
    3. Weller SC
    . Informed decision making changes test preferences for colorectal cancer screening in a diverse population. Ann Fam Med 2010;8:141–50.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. DeBourcy A,
    2. Lichtenberger S,
    3. Felton S,
    4. et al
    . Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening. J Gen Intern Med 2008;23:169–74.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Gupta S,
    2. Halm EA,
    3. Rockey DC,
    4. et al
    . Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: A randomized clinical trial. JAMA Intern Med 2013;173:1725–32.
    OpenUrlPubMed
  27. 27.↵
    1. Allison JE,
    2. Fraser CG,
    3. Halloran SP,
    4. et al
    . Population screening for colorectal cancer means getting FIT: The past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver 2014;8:117–30.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Vart G,
    2. Banzi R,
    3. Minozzi S
    . Comparing participation rates between immunochemical and guaiac faecal occult blood tests: A systematic review and meta-analysis. Prev Med 2012;55:87–92.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Tinmouth J,
    2. Lansdorp-Vogelaar I,
    3. Allison JE
    . Faecal immunochemical tests versus guaiac faecal occult blood tests: What clinicians and colorectal cancer screening programme organisers need to know. Gut 2015;64:1327–37.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    World Endoscopy Organization. FIT for Screening. 2017. Available from: http://www.worldendo.org/about-us/committees/colorectal-cancer-screening/ccs-testpage2-level4/fit-for-screening. Accessed Jan 31, 2017.
  31. 31.↵
    1. Chubak J,
    2. Bogart A,
    3. Fuller S,
    4. et al
    . Uptake and positive predictive value of fecal occult blood tests: A randomized controlled trial. Prev Med 2013;57:671–8.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Daly JM,
    2. Bay CP,
    3. Levy BT
    . Evaluation of fecal immunochemical tests for colorectal cancer screening. J Prim Care Community Health 2013;4:245–50.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Lee JK,
    2. Liles EG,
    3. Bent S,
    4. et al
    . Accuracy of fecal immunochemical tests for colorectal cancer: Systematic review and meta-analysis. Ann Intern Med 2014;160:171.
    OpenUrlPubMed
  34. 34.↵
    1. Creswell JW,
    2. Plano Clark VL
    . Designing and Conducting Mixed Methods Research. 2nd ed. Thousand Oaks, CA: Sage Publications, Inc; 2011.
  35. 35.↵
    1. Creswell JW,
    2. Klassen AC,
    3. Plano Clark VL,
    4. et al
    . Best practices for mixed methods research in the health sciences. Office of Behavioral and Social Sciences Research (OBSSR); 2011.
  36. 36.↵
    1. Nay B,
    2. Knivila K
    . Oregon's Coordinated Care Organizations—Health system transformation or managed care revisited? Insights. Williamette Management Associates; 2013.
  37. 37.↵
    OregonLaws.org. 2015 ORS 414.627 Community Advisory Councils. 2015.
  38. 38.↵
    1. McConnell K
    . Oregon's Medicaid coordinated care organizations. JAMA 2016;315:869–70.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. McConnell KJ,
    2. Renfro S,
    3. Chan BK,
    4. et al
    . Early performance in Medicaid accountable care organizations: A comparison of Oregon and Colorado. JAMA Intern Med 2017;177(4):538–545.
    OpenUrl
  40. 40.↵
    Oregon Health Authority. CCO Metrics. 2013.
  41. 41.↵
    Oregon Health Authority. Oregon's health system transformation: CCO metrics 2015 final report. 2016.
  42. 42.↵
    Columbia Gorge Regional Community Health Assessment [PDF]. December 2013.
  43. 43.↵
    1. Worthley DL,
    2. Cole SR,
    3. Mehaffey S,
    4. et al
    . Participant satisfaction with fecal occult blood test screening for colorectal cancer. J Gastroenterol Hepatol 2007;22:142–3.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Deutekom M,
    2. van Rossum LG,
    3. van Rijn AF,
    4. et al
    . Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: The patient perspective. Scand J Gastroenterol 2010;45:1345–9.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Neergaard MA,
    2. Olesen F,
    3. Andersen RS,
    4. et al
    . Qualitative description—The poor cousin of health research? BMC Med Res Methodol 2009;9(1):52.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Sandelowski M
    . Whatever happened to qualitative description? Res Nurs Health 2000;23:334–40.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    File Update Summary: Colorectal Cancer: Screening. July 2015. Available from: https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/colorectal-cancer-screening.
  48. 48.↵
    1. Cole SR,
    2. Young GP,
    3. Esterman A,
    4. et al
    . A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003;10:117–22.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Gordon NP,
    2. Green BB
    . Factors associated with use and non-use of the fecal immunochemical test (fit) kit for colorectal cancer screening in response to a 2012 outreach screening program: A survey study. BMC Pub Health 2015;15(1):546.
    OpenUrl
  50. 50.↵
    1. O'Sullivan I,
    2. Orbell S
    . Self-sampling in screening to reduce mortality from colorectal cancer: A qualitative exploration of the decision to complete a faecal occult blood test (FOBT). J Med Screen 2004;11:16–22.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Coronado GD,
    2. Sanchez J,
    3. Petrik A,
    4. et al
    . Advantages of wordless instructions on how to complete a fecal immunochemical test: Lessons from patient advisory council members of a federally qualified health center. Journal Cancer Educ 2014;29:86–90.
    OpenUrl
  52. 52.
    1. Chiang TH,
    2. Lee YC,
    3. Tu CH,
    4. et al
    . Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. CMAJ 2011;183:1474–81.
    OpenUrlAbstract/FREE Full Text
  53. 53.
    1. Cheng TI,
    2. Wong JM,
    3. Hong CF,
    4. et al
    . Colorectal cancer screening in asymptomaic adults: Comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. J Formos Med Assoc 2002;101:685–90.
    OpenUrlPubMed
  54. 54.
    Benefits. The new recommended technology for occult blood detection to aid in colorectal cancer screening. Available from: http://hemosure.com/sales/benefits/. Accessed March 23, 2017.
  55. 55.
    1. Smith A,
    2. Young GP,
    3. Cole SR,
    4. et al
    . Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 2006;107:2152–9.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.
    1. Allison JE,
    2. Sakoda LC,
    3. Levin TR,
    4. et al
    . Screening for colorectal neoplasms with new fecal occult blood tests: Update on performance characteristics. J Natl Cancer Inst 2007;99:1462–70.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.
    1. Ko CW,
    2. Dominitz JA,
    3. Nguyen TD
    . Fecal occult blood testing in a general medical clinic: Comparison between guaiac-based and immunochemical-based tests. Am J Med 2003;115:111–4.
    OpenUrlPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords